# Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS

> **NCT04557085** · PHASE3 · UNKNOWN · sponsor: **SK Life Science, Inc.** · enrollment: 540 (estimated)

## Conditions studied

- Partial Seizure
- Focal Seizure

## Interventions

- **DRUG:** Cenobamate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04557085
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-08
- **Primary completion:** 2024-02
- **Final completion:** 2025-03
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557085, "Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04557085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*